Colorectal cancer candidate drug RCC-33 reduces tumor volume in mice by 27%

Colorectal cancer, also known as colorectal cancer, is a cancer that originates in the colon or rectum (which is part of the large intestine).
may invade or transfer to other parts of the body due to abnormal cell growth.
may include blood in the faeces, changes in detocal habits, weight loss, and tiredness.
Pharmaceuticals announced today that its ongoing in vivo study, which assesses the potential of its drug candidate, RCC-33, to treat colorectal cancer has been interim results.
results showed a 27 percent reduction in tumor volume in mice exposed to RCC-33 compared to control mice.
both groups were vaccinated against colorectal cancer cells and RCC-33 injections in the periduct (IP) began on the 5th day.
after 5 days of treatment, the difference between the tumor volumes of the two groups of mice was observed, and after 12 days of treatment, the tumor volume of the RCC-33 mice was reduced by 27% (p=0.022).
study is under way.
is the third most common cancer in the world," said Gabriel Yariv, president and chief operating officer of Cannabics.
67 per cent of patients currently receiving treatment can survive for five years or more.
our goal is to further improve the survival time of patients."